Expertise in
24
conditions

Dr. Lawrence A. Gervasi

Urology
Office
6900 Pearl Rd Fl 2, 
Middleburg Heights, OH 
Accepting New Patients
Offers Telehealth
Expertise in
24
conditions
Office
6900 Pearl Rd Fl 2, 
Middleburg Heights, OH 

Overview

Lawrence Gervasi is a Urologist practicing medicine in Middleburg Heights, Ohio.

Dr. Gervasi is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Non-Muscle Invasive Bladder Cancer, UPJ Obstruction, Muscle Invasive Bladder Cancer, Prostate Cancer, and Ureteroscopy.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 9 clinical trials. Dr. Gervasi is currently accepting new patients.

Specialties

Urology

Licenses

Urology in OH

Hospital Affiliations

Uh Cleveland Medical Center
Parma Community General Hospital
Southwest General Health Center

Languages Spoken

English
Filipino
German
Greek

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
SummaCare
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 23 Less Insurance Carriers -

Locations

Office
6900 Pearl Rd Fl 2, Middleburg Heights, OH 44130

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
Enrollment Status: Active_not_recruiting
Publish Date: May 11, 2026
Intervention Type: Drug
Study Drug: UGN-102
Study Phase: Phase 3
A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBC
A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBC
Enrollment Status: Completed
Publish Date: January 14, 2026
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Enrollment Status: Terminated
Publish Date: June 06, 2024
Intervention Type: Drug, Procedure
Study Drug: Mitomycin C
Study Phase: Phase 3
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: VERU-111, Enzalutamide, Abiraterone, Darolutamide and Apalutamide
Study Phase: Phase 3
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Enrollment Status: Terminated
Publish Date: May 19, 2023
Intervention Type: Drug
Study Drug: VERU-100
Study Phase: Phase 1/Phase 2
Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria
Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria
Enrollment Status: Terminated
Publish Date: May 17, 2023
Intervention Type: Drug, Biological, Combination product
Study Phase: Phase 1/Phase 2
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Enrollment Status: Terminated
Publish Date: June 23, 2022
Intervention Type: Diagnostic test
PURSUIT: Prospective US Radiofrequency SUI Trial
PURSUIT: Prospective US Radiofrequency SUI Trial
Enrollment Status: Unknown
Publish Date: July 26, 2021
Intervention Type: Device
Study Phase: Not Applicable
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Enrollment Status: Completed
Publish Date: February 05, 2019
Intervention Type: Drug
Study Phase: Not Applicable
View 8 Less Clinical Trials

3 Total Publications

Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial.
Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial.
Journal: Targeted oncology
Published: March 17, 2025
Similar Doctors
Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (12.2 miles away)
216-444-5598
Languages Spoken:
English, Italian, Portuguese
See accepted insurances
Accepting New Patients
Offers Telehealth

Riccardo Autorino is a Urologist practicing medicine in Cleveland, Ohio. Dr. Autorino is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Upper Tract Urothelial Carcinoma (UTUC), Urothelial Cancer, Enlarged Prostate (BPH), Nephrectomy, and Prostatectomy. Dr. Autorino is currently accepting new patients.

Expertise in
31
conditions
Expertise in
31
conditions
Referral may be required
Before you request

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (12.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jihad Kaouk is a Urologist practicing medicine in Cleveland, Ohio. Dr. Kaouk is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Horseshoe Kidney, Nephrectomy, and Prostatectomy. Dr. Kaouk is board certified in American Board Of Urology, 2013. Dr. Kaouk is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Office

6900 Pearl Rd Fl 2, 
Cleveland, OH 
 (0.2 miles away)
440-845-0900
Languages Spoken:
English, Arabic, Arabic - Jordanian
See accepted insurances
Accepting New Patients
Offers Telehealth

Adonis Hijaz is a Urologist practicing medicine in Cleveland, Ohio. Dr. Hijaz is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Urinary Incontinence, Stress Urinary Incontinence, Uterine Prolapse, Sacral Nerve Stimulation, and Ureteroscopy. Dr. Hijaz is currently accepting new patients.

Frequently Asked Questions about Dr. Lawrence A. Gervasi

How do I make an appointment with Dr. Lawrence A. Gervasi?

You can book an appointment with Dr. Lawrence A. Gervasi by calling their office at 440-845-0900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lawrence A. Gervasi a top-rated expert for Non-Muscle Invasive Bladder Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lawrence A. Gervasi is classified as an Distinguished expert for Non-Muscle Invasive Bladder Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lawrence A. Gervasi specialize in?

While Dr. Lawrence A. Gervasi is a Urology, they have specific expertise in Non-Muscle Invasive Bladder Cancer, UPJ Obstruction, and Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Urology.

Does Dr. Lawrence A. Gervasi participate in research or clinical trials?

Yes. Dr. Lawrence A. Gervasi has published 3 articles and abstracts on conditions like Non-Muscle Invasive Bladder Cancer. You can view a list of Dr. Lawrence A. Gervasi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Lawrence A. Gervasi accept my insurance?

Dr. Lawrence A. Gervasi accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 440-845-0900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gervasi's expertise for a condition
ConditionClose
    View All 13 Distinguished Conditions
    View All 11 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile